Chemotherapy-induced hemorrhagic cystitis is characterized by bladder pain and 2 voiding dysfunction caused by hemorrhage and inflammation. Of currently available 3 therapies, prophylactic 2-mercaptoethanesulfonic acid (MESNA) has limited efficacy 4 and cannot treat pre-existing lesions. Therefore, novel therapeutic options to treat 5 hemorrhagic cystitis are needed. We previously reported that systemic administration of 6 the Schistosomiasis haematobium-derived protein H-IPSE H06 (IL-4-inducing principle 7 from Schistosoma mansoni eggs), is superior to 3 doses of MESNA in alleviating 8 hemorrhagic cystitis. Based on prior reports by others on S. mansoni IPSE and 9 additional work by our group, we reasoned that H-IPSE H06 mediates its effects on 1 0 hemorrhagic cystitis by binding IgE on basophils and inducing IL-4 expression, 1 1
Mice were anesthetized with 2% continuous isoflurane on a heating pad. applied to the incision. The mice were recovered on a heating pad. Twenty-four hours 2 1 later mice were injected with 400 mg/kg ifosfamide (Sigma-aldrich, St. Louis, MO). Mice Recombinant IPSE protein was generated as previously described (1,2). One 3 9 milligram of plasmid DNA was purified using a GeneElute HP endotoxin-free plasmid 4 0
Maxiprep kit (Sigma-Aldrich), and incubated with 3 mg linear 25 kDa polyethylenimine 4 1 (PolySciences, Warrington, PA) at 1 mg/mL. Finally, the plasmid was diluted in 10 mL FreeStyle 293 Medium (Thermo Fisher Scientific, Waltham, MA, USA) ( Figure 2A ). Centrifugal Filter Unit (EMD Millipore, Billerica, MA, USA) followed by purification with a 4 9
Hiload 16/600 Superdex 200 Column (GE Healthcare, Waukesha, WI, USA). Nuclear 5 0 localization mutants were generated using site-directed mutagenesis. These mutants Hiload columns were cleaned with 0.5 M NaoH for greater than 2 hours of continuous Purified protein was separated on 4-20% gradient gels by SDS-PAGE in 15 µL for 1 hour at room temperature followed by 3 additional washes. Imaging was performed Basophil activation was quantified as previously described (23). RS-ATL8 cells were 7 0 cultured in 10 mL MEM (GIBCO, USA), supplemented with 5% vv v/v heat-inactivated 7 1 FCS (GIBCO, USA), 100 U/mL penicillin, and 100 µg/mL streptomycin (Sigma, UK) and Visceral pain scores were assigned as previously described (10). The observer 8 4 was blinded to mouse treatment assignments prior to assessments. Mice were placed in 8 5 clean cages and acclimated for 30 min. For spontaneous pain scoring, mice were 8 6 observed for 60 seconds and given a cumulative spontaneous pain score based on the pain score is 15. Pain scores were collected at baseline (prior to bladder wall injection), 9 0 and 10 hours after ifosfamide was administered. Evoked pain scores were collected in a blinded fashion to assess for referred 9 3 hyperalgesia. We adopted the up-down approach as previously described (6, 13). An 9 4 electronic Von Frey filament (BioSeb, Pinellas Park, Florida) was applied to the right 9 5 hind footpad of the mouse for 5 seconds until the mouse displayed rapid withdrawal of 9 6 the paw, jumping, or licking of the paw. The 50% withdrawal threshold was then 9 7 calculated from an average of 3 measurements. Results are tabulated as the difference 9 8 between baseline and post-ifosfamide values.
9
Voided Spot on Paper Assay 1 0 0
Voided spot on paper assays were performed as previously described (1, was covered with wire mesh to prevent mice from tearing or ripping the paper. Food performed with ImageJ Fiji (https://fiji.sc/). Corner voiding was assessed by assigning 1 1 0 5% of the total paper area to each corner. Central voiding was assessed by assigning 1 1 1 40% of the total area to the center of the filter paper. IPSE H03 or H-IPSE H03NLS were added to the cell media at the following concentrations: 1 1 5 0.0655 pmol (1 ng/ml), 0.655 pmol (10 ng/ml), 6.55 pmol (100 ng/ml), 65.5 pmol (1000 1 1 6 ng/ml), or PBS for control. 5-(and 6)-Carboxyfluorescein diacetate succinimidyl ester 1 1 7 (CFSE) assays were then performed according to manufacturer's instructions Biosciences, San Jose, CA). Flow cytometric analysis was performed using FlowJo 3 We previously demonstrated that M-IPSE activates basophils in vitro through NF-4 AT (23). This pathway is implicated in basophil and mast cell expression of IL-4, which 5 we have observed in vivo in mice administered H-IPSE H06 (17). Moreover, we have also 6 noted that ifosfamide-challenged mice given H-IPSE H06 are protected from several 7 pathogenic aspects of hemorrhagic cystitis in an IL-4-dependent fashion (17). Thus, we 8 sought to demonstrate that H-IPSE H03 and H-IPSE H06 , which are both S. haematobium 9 orthologs of M-IPSE, also stimulate IL-4-associated reporter gene expression in vitro. NF-AT activation, which is associated with IL-4 secretion in basophils ( Figure 2B ).
5
Having confirmed that H-IPSE H03 triggers IL-4-associated pathways in cultured 1 6 basophils, we next sought to determine the therapeutic efficacy of H-IPSE H03 in the 1 7 mouse model of ifosfamide-induced hemorrhagic cystitis. 
H-IPSE H03 dampens chemotherapy-induced increases in bladder wet weight 1 9
We assessed for an increase in bladder wet weight caused by hemorrhage, 2 0 edema and cellular infiltration following ifosfamide injection. Ifosfamide administration 2 1 caused a statistically significant increase in bladder wet weight compared to controls 2 2 (Figure 2A, 2B; n=8, p<0 .001) H-IPSE H03 bladder wall injection significantly reversed the 2 3 8 increase in bladder wet weight caused by ifosfamide in bladder wall injected mice but 2 4 not mice that received tail vein injection (p=0.02 and N.S., respectively). The beneficial 2 5 effect of IPSE on bladder wet weight was reversed by anti-IL4 antibody (p<0.001).
6
However, IPSE H03NLS also ameliorated ifosfamide-induced increases in bladder wet 2 7 weight, regardless of mode of administration, suggesting that the therapeutic effect of 2 8 IPSE on bladder wet weight is mediated by IL-4, but not dependent on IPSE 2 9 translocation into the nucleus.
0
Tail vein injection results were distinct from bladder wall injection in two ways.
1
After tail vein H-IPSE H03 injection bladder wet weights decreased but remained 3 2 significantly higher than non-ifosfamide-exposed controls ( Figure 2B; p=0.03) . We next sought to determine whether H-IPSE H03 administration had an effect on 3 8 ifosfamide-induced bladder pain. We first measured referred hyperalgesia using von 3 9
Frey filament testing. Mice injected with ifosfamide had greater evoked pain responses 4 0 than those of control mice (Figure 3 ). H-IPSE H03 bladder wall injection increased the 4 1 withdrawal threshold, i.e., reversed allodynia caused by ifosfamide injection (p<0.05).
2
When neutralizing anti-IL-4 antibody was co-administered with H-IPSE H03 , the protective Mice are prey animals and preferentially void in the corner of their enclosures as 5 0 a predator avoidance strategy. We assessed for voiding dysfunction caused by from ifosfamide treatment (p=0.07 vs. control).
7
Ifosfamide administration non-significantly increased the percentage of voids in Therefore, novel therapies need to be developed to fulfill this unmet need. Schistosoma haematobium worms lay eggs in the bladder and other pelvic organs.
3
Deposited eggs must traverse the host bladder wall in order to be released in the urine.
4
Although urogenital schistosomiasis itself causes a form of hemorrhagic cystitis, 1 5 hematuria can be variable or even absent (24). We reasoned that host 1 6 immunomodulation by S. haematobium egg products allow the parasite to complete its 1 7 life cycle without causing severe morbidity to its host, including hemorrhagic cystitis 1 8 (10). Specifically, we postulated that S. haematobium eggs can accomplish this by 1 9 secreting H-IPSE orthologs in order to modulate the host immune response. In a prior study we demonstrated the clinical potential of exploiting the anti- with PBS (control) or ifosfamide ("ifosfamide" or "ifos"). Some mice received neutralizing 1 5 anti-IL4 antibody (αIL4) 30 minutes prior to ifosfamide. Bladders were collected and 1 6 weighed 12 hours following ifosfamide injection to assess for edema and hemorrhage. 
